دورية أكاديمية
Ultrathin-strut versus thin-strut stent healing and outcomes in preclinical and clinical subjects.
| العنوان: | Ultrathin-strut versus thin-strut stent healing and outcomes in preclinical and clinical subjects. |
|---|---|
| المؤلفون: | Ikegami R; Division of Cardiology, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Piao Z; Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA., Iglesias JF; Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland., Pilgrim T; Bern University Hospital, Bern, Switzerland., Ha K; Masonic Medical Research Institute, Utica, NY, USA.; Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA., McCarthy JR; Masonic Medical Research Institute, Utica, NY, USA.; Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA., Castellanos MI; Klink Fur Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universitat München, München, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, München, Germany., Kassab MB; Division of Cardiology, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA., Albagdadi MS; Division of Cardiology, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.; Department of Medicine, Division of Cardiology, University of Toronto, Toronto, Canada., Mauskapf A; Division of Cardiology, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA., Spicer G; Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA., Kandzari DE; Piedmont Heart Institute, Atlanta, GA, USA., Edelman ER; Harvard-Massachusetts Institute of Technology Health Sciences and Technology, Cambridge, MA, USA.; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA., Libby P; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA., Heg D; CTU Bern, Bern University, Bern, Switzerland., Joner M; Klink Fur Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universitat München, München, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, München, Germany., Tearney GJ; Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.; Harvard-Massachusetts Institute of Technology Health Sciences and Technology, Cambridge, MA, USA., Jaffer FA; Division of Cardiology, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.; Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. |
| المصدر: | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2024 May 20; Vol. 20 (10), pp. e669-e680. Date of Electronic Publication: 2024 May 20. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Société Europa édition Country of Publication: France NLM ID: 101251040 Publication Model: Electronic Cited Medium: Internet ISSN: 1969-6213 (Electronic) Linking ISSN: 1774024X NLM ISO Abbreviation: EuroIntervention Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Toulouse : Société Europa édition, c2005- |
| مواضيع طبية MeSH: | Drug-Eluting Stents* , Percutaneous Coronary Intervention*/instrumentation , Percutaneous Coronary Intervention*/methods , Sirolimus*/therapeutic use , Sirolimus*/administration & dosage , Sirolimus*/pharmacology , Tomography, Optical Coherence*, Animals ; Rabbits ; Humans ; Treatment Outcome ; Prosthesis Design ; Coronary Artery Disease/therapy ; Coronary Artery Disease/diagnostic imaging ; Male ; Absorbable Implants ; Female ; Wound Healing |
| مستخلص: | Background: Compared with thin-strut durable-polymer drug-eluting stents (DP-DES), ultrathin-strut biodegradable-polymer sirolimus-eluting stents (BP-SES) improve stent-related clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). Reduced stent strut thickness is hypothesised to underlie these benefits, but this conjecture remains unproven. Aims: We aimed to assess the impact of strut thickness on stent healing and clinical outcomes between ultrathin-strut and thin-strut BP-SES. Methods: First, we performed a preclinical study of 8 rabbits implanted with non-overlapping thin-strut (diameter/thickness 3.5 mm/80 μm) and ultrathin-strut (diameter/thickness 3.0 mm/60 μm) BP-SES in the infrarenal aorta. On day 7, the rabbits underwent intravascular near-infrared fluorescence optical coherence tomography (NIRF-OCT) molecular-structural imaging of fibrin deposition and stent tissue coverage, followed by histopathological analysis. Second, we conducted an individual data pooled analysis of patients enrolled in the BIOSCIENCE and BIOSTEMI randomised PCI trials treated with ultrathin-strut (n=282) or thin-strut (n=222) BP-SES. The primary endpoint was target lesion failure (TLF) at 1-year follow-up, with a landmark analysis at 30 days. Results: NIRF-OCT image analyses revealed that ultrathin-strut and thin-strut BP-SES exhibited similar stent fibrin deposition (p=0.49) and percentage of uncovered stent struts (p=0.63). Histopathological assessments corroÂborated these findings. In 504 pooled randomised trial patients, TLF rates were similar for those treated with ultrathin-strut or thin-strut BP-SES at 30-day (2.5% vs 1.8%; p=0.62) and 1-year follow-up (4.3% vs 4.7%; p=0.88). Conclusions: Ultrathin-strut and thin-strut BP-SES demonstrate similar early arterial healing profiles and 30-day and 1-year clinical outcomes. |
| References: | JACC Cardiovasc Interv. 2020 Oct 12;13(19):2314-2316. (PMID: 33032722) Lancet. 2014 Dec 13;384(9960):2111-22. (PMID: 25189359) Nat Commun. 2017 Jul 13;8(1):75. (PMID: 28706202) Circulation. 2011 Apr 5;123(13):1400-9. (PMID: 21422389) J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. (PMID: 16814667) Lancet. 2017 Oct 21;390(10105):1843-1852. (PMID: 28851504) Lancet. 2019 Oct 5;394(10205):1243-1253. (PMID: 31488372) Lancet. 2019 Jun 22;393(10190):2503-2510. (PMID: 31056295) Heart. 2003 Feb;89(2):133-8. (PMID: 12527658) EuroIntervention. 2016 Dec 10;12(11):e1343-e1354. (PMID: 26690319) Expert Rev Med Devices. 2017 Oct;14(10):773-788. (PMID: 28889769) JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. (PMID: 24239202) Int J Cardiovasc Imaging. 2015 Feb;31(2):259-68. (PMID: 25341407) Circulation. 2001 Jun 12;103(23):2816-21. (PMID: 11401938) Eur Heart J. 2015 Dec 18;38(6):447-455. (PMID: 26685129) J Am Coll Cardiol. 2011 Oct 4;58(15):1569-77. (PMID: 21924575) Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1500-10. (PMID: 17510464) Atherosclerosis. 2022 Mar;344:31-39. (PMID: 35134654) JACC Cardiovasc Interv. 2021 Mar 22;14(6):639-648. (PMID: 33727005) Arterioscler Thromb Vasc Biol. 2021 Jul;41(7):e385-e398. (PMID: 34011166) Eur Radiol. 2008 Sep;18(9):1995-2005. (PMID: 18425519) BMC Cardiovasc Disord. 2018 Aug 15;18(1):170. (PMID: 30111289) EuroIntervention. 2010 Nov;6(5):630-7. (PMID: 21044918) JACC Cardiovasc Interv. 2021 Nov 22;14(22):2461-2473. (PMID: 34794652) Am Heart J. 2023 Sep;263:73-84. (PMID: 37192697) Eur Heart J. 2021 Jul 15;42(27):2643-2654. (PMID: 34002202) |
| تواريخ الأحداث: | Date Created: 20240522 Date Completed: 20240522 Latest Revision: 20240524 |
| رمز التحديث: | 20240524 |
| مُعرف محوري في PubMed: | PMC11100507 |
| DOI: | 10.4244/EIJ-D-23-00563 |
| PMID: | 38776143 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1969-6213 |
|---|---|
| DOI: | 10.4244/EIJ-D-23-00563 |